Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

April 30, 2007

Study Completion Date

July 31, 2011

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

DRUG

cisplatin

Given IV

DRUG

irinotecan hydrochloride

Given IV

BIOLOGICAL

bevacizumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

Cancer and Leukemia Group B, Chicago

Rhode Island Hospital, Providence

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00118235 - Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter